February 22, 2010 - EnzymeRx Provides Clinical Updates on Pegsitacase
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, today announced that it has launched its first clinical study of pegsitacase (formerly Uricase-PEG 20).
November 2, 2009 - EnzymeRx Launches Clinical Study of Pegsitacase
EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, today announced that it has launched its first clinical study of pegsitacase.
September 25, 2009 - EnzymeRx Announces its IND for Pegsitacase Becomes Effective
EnzymeRx, LLC, a clinical-stage biotechnology company, today announced that its Investigational New Drug (IND) application for pegsitacase, filed with the U.S. Food and Drug Administration(FDA) last month, has become effective.
March 19, 2009 - EnzymeRx Announces Management Appointments in the areas of Biologics Manufacturing and Pre-Clinical R&D
EnzymeRx today announced two significant additions to its management team.
May 28, 2008 - EnzymeRx Announces Receipt of $14 million Capital Investment and Acquisition of Pegylated Uricase
EnzymeRx, a clinical stage biotechnology company, today announced it has raised $14 million from funds managed by Pequot Capital Management and has acquired worldwide rights, excluding Taiwan, to pegsitacase from Polaris Pharmaceuticals, which will also hold an equity stake in EnzymeRx.